J Clin Endocrinol Metab 2009;94:96572.ArticlePubMed 16
It has been licensed for aiding weight loss in non-diabetic people under the trade name Wegovy, strictly indicated for patients with obesity or overweight with diagnosed weight-related comorbidities [6, 7]
Bottom Line The largest patient-voice analysis of GLP-1 drugs to date confirms that gastrointestinal side effects dominate the real-world experience and surfaces two underrecognized signal clusters: reproductive and temperature symptoms
Good candidates for semaglutide or tirzepatide Both semaglutide and tirzepatide weight loss injections are generally ideal for both men and women who: Have a BMI of 27 or higher with weight-related health conditions like diabetes, high blood pressure, or sleep apnea
This means that your dosing schedule for weight loss might be different from others, so you will work with your healthcare provider to find the right therapeutic dose for you
However, understanding the differences between the two can help patients and healthcare providers make informed decisions
![PDF] Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial](https://figures.semanticscholar.org/898978c1b0543b943d605e293f5296fb7568cee7/9-Table2-1.png)
